MedTrace Logo

Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3

NCT04426149 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-06-11

No results posted yet for this study

Summary

There are no clinically established treatments which have been proven to delay the disease progression in spinocerebellar ataxia (SCA) 3. Most available treatments are only for symptom alleviation, and thus the majority of patients will eventually progress to needing and wheel chair and eventually bedridden.

As trehalose appear to be potentially promising treatment in SCA, the investigators aim to conduct this study using oral trehalose in our genetically confirmed SCA 3 patients.

Conditions

  • Spinocerebellar Ataxia 3

Interventions

DIETARY_SUPPLEMENT

trehalose

patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily

Sponsors & Collaborators

  • National University of Malaysia

    lead OTHER

Principal Investigators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-07
Primary Completion
2018-09-07
Completion
2018-09-07

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04426149 on ClinicalTrials.gov